Hospital Universitario de Getafe -ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

2023

  1. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  2. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  4. Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series

    Gastroenterologia y Hepatologia

2022

  1. SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS

    Frontiers in Immunology, Vol. 13

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Impact of significant paravalvular leaks after transcatheter aortic valve implantation on anaemia and mortality

    Heart, Vol. 107, Núm. 6, pp. 497-502

  3. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

2020

  1. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. e513-e522

2018

  1. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy

    Modern Pathology, Vol. 31, Núm. 8, pp. 1318-1331

  2. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

  3. Reliability and validity of the Spanish version of the IDEAL Schedule for assessing care needs in dementia: Cross-sectional, multicenter study

    International Journal of Geriatric Psychiatry, Vol. 33, Núm. 3, pp. 482-488

2012

  1. Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome

    PLoS Genetics, Vol. 8, Núm. 2

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Lesiones importadas del sistema nervioso

    Medicine, Vol. 10, Núm. 55, pp. 3780-3784

2008

  1. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

    European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235

2007

  1. Sucesos adversos en cirugía general y de aparato digestivo en los hospitales españoles

    Cirugia Espanola, Vol. 82, Núm. 5, pp. 268-277

  2. Un aspecto crítico de la calidad: Los sucesos adversos en los hospitales españoles: Resultados del estudio eneas

    Medicina Preventiva, Vol. 13, Núm. SPEC. ISS., pp. 64-70

2006

  1. Erratum: Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients (Annals Hematology (2006) 10.1007/s00277-005-0073-1)

    Annals of Hematology